我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
64
5 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1951
进行中（未招募）
4
6.3%
已完成
19
29.7%
尚未招募
1
1.6%
招募中
16
25.0%
Unknown
23
35.9%
撤回
暂无批准数据
- Nemtabrutinib demonstrates encouraging efficacy in patients with relapsed or refractory follicular lymphoma, according to findings from the BELLWAVE-003 phase 2 trial. - The study, presented at the 2024 ASH Annual Meeting, highlights the potential of nemtabrutinib as a treatment option for this patient population. - Safety data from the trial indicate a manageable toxicity profile, supporting the continued investigation of nemtabrutinib in follicular lymphoma. - Further research is warranted to confirm these findings and explore the optimal use of nemtabrutinib in the treatment landscape.
